Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Chronic Pruritus Therapeutics Market Growth Performance Trended Historically, And What Lies Ahead?
In the past few years, the chronic pruritus therapeutics market has seen robust growth. The market size is projected to increase from $10.17 billion in 2024 to $10.91 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.3%. The historic growth can be credited to factors such as heightened instances of chronic pruritus, a surge in the need for viable treatments, an uptick in regulatory approvals, an increase in approved products, and a rise in mergers, partnerships, and takeovers among industry players.
In the next few years, the chronic pruritus therapeutics market is slated to experience robust growth, reaching a value of $14.36 billion in 2029, with a CAGR of 7.1%. The growth during the projected period can be linked to multiple factors such as the increase in awareness, prevalence of atopic dermatitis, a growing emphasis on personalized medication, the rise in dermatological conditions, and an expanding patient population. The forecast period also foresees major trends like the launch of innovative drugs, the creation of unique biologics and targeted treatments, advancements in technology, the integration of sophisticated drug delivery systems, partnerships between pharma companies and research bodies, and the advent of digital health solutions such as telemedicine.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp
What Are the Core Market Drivers Propelling Growth in the Chronic Pruritus Therapeutics Industry?
The growth of the chronic pruritus therapeutics market is anticipated to be driven by the increasing instances of atopic dermatitis. Characterized by redness, itching, dryness, and irritation, atopic dermatitis (AD) is a persistent skin condition caused by chronic inflammation, primarily affecting individuals with a familial history of allergies, asthma, or hay fever. Various factors, such as genetic predisposition, environmental alterations, lifestyle elements, the hygiene theory, heightened allergen exposure, and imbalances in the skin microbiome, contribute to the escalating prevalence of atopic dermatitis. Chronic pruritus therapeutics plays a crucial role in managing the continuous itchiness associated with AD by focusing on the fundamental inflammatory pathways, decreasing skin irritation, and enhancing patient comfort. For example, in 2022, the International Eczema Council, a nonprofit organization based in the US, reported that approximately 223 million people worldwide were afflicted with atopic dermatitis (GBD 2022), including 43 million children between the ages of 1-4, underlining the significant occurrence of this condition in early childhood. As a result, the escalating number of atopic dermatitis cases is fuelling the growth of the chronic pruritus therapeutics market.
How Is the Chronic Pruritus Therapeutics Market Segmented?
The chronic pruritus therapeuticsmarket covered in this report is segmented –
1) By Product Type: Corticosteroid; Antihistamine; Local Anesthetic; Counterirritant; Immunosuppressant; Calcineurin Inhibitors; Other Product Types
2) By Disease Type: Atopic Dermatitis; Allergic Contact Dermatitis; Urticaria; Other Disease Types
3) By Distribution Channel: Hospital Pharmacies; Drug stores And Retail Pharmacies; Online Providers
Subsegments:
1) By Corticosteroid: Topical Corticosteroids; Oral Corticosteroids; Injectable Corticosteroids
2) By Antihistamine: First-Generation Antihistamines; Second-Generation Antihistamines
3) By Local Anesthetic: Topical Local Anesthetics; Injectable Local Anesthetics
4) By Counterirritant: Menthol-Based Counterirritants; Camphor-Based Counterirritants
5) By Immunosuppressant: Systemic Immunosuppressants; Topical Immunosuppressants
6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy; Pimecrolimus-Based Therapy
7) By Other Product Types: Biologic Therapies; Emerging Novel Therapies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21147&type=smp
Which Regions Are Driving the Next Phase of the Chronic Pruritus Therapeutics Market Growth?
North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Market Trends and Innovations Are Shaping the Future of the Chronic Pruritus Therapeutics Industry?
Leading companies in the chronic pruritus therapeutics market are channeling their efforts into creating novel formulations, such as intravenous (IV) injections, to improve treatment effectiveness and speed up patient relief. IV injection is a proven method in pruritus treatment, allowing for direct delivery of drugs like antihistamines or corticosteroids into the patient’s circulation to rapidly ease itchiness and lessen inflammation. For example, in September 2023, a US firm known as Cara Therapeutics Inc. which engages in producing therapeutics, announced their associate company, Maruishi Pharmaceutical Co. Ltd, a pharmaceutical enterprise originating from Japan, has secured approval for Korsuva IV injection syringe, a pruritus treatment for hemodialysis patients, from the Japan’s Ministry of Health, Labour and Welfare, a government agency in Japan. This approval was cemented on the back of successful Phase 3 clinical trial results orchestrated by Maruishi alongside Kissei Pharmaceutical Co., Ltd. The treatment demonstrated substantial enhancements in itchiness ratings when compared to a placebo and patients tolerated it well. As a result of this approval, a $1.5 million milestone payment is due to Cara Therapeutics, the creator of Korsuva, in line with their licensing agreement with Maruishi.
View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report
How Is the Chronic Pruritus Therapeutics Market Defined and What Are Its Core Parameters?
Chronic pruritus therapy refers to treatments aimed at managing or alleviating persistent itching (pruritus) that lasts for six weeks or more. Chronic pruritus is managed with a combination of therapies that are tailored to the specific underlying cause, and treatment can be adjusted based on how the patient responds.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21147
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model